BMO Capital Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $310

Benzinga · 3d ago
BMO Capital analyst Malcolm Hoffman initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Outperform rating and announces Price Target of $310.